Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL1916 Target Snapshot

Alpha-2C adrenergic receptor · SINGLE PROTEIN · Homo sapiens

2,922Compounds
378Assays
157Approved Drugs
2,923.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Alpha-2C adrenergic receptor shows clinical signal disease relevance led by Alzheimer disease. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt P18825. Start with Alzheimer disease, then reuse UniProt P18825 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with Alzheimer disease, then reuse UniProt P18825 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13 1 linked drug
Open source guide
Disease program
Alzheimer disease

Alpha-2C adrenergic receptor shows clinical signal disease relevance led by Alzheimer disease. 1 linked drug remains visible in the same block.

Start review with Alzheimer disease because it currently carries clinical signal support. Linked drugs include ORM-12741. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Clinical signal Open Targets-ready proxy 1 linked drug
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Alpha-2C adrenergic receptor as ChEMBL target CHEMBL1916, mapped to UniProt P18825. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Alpha-2C adrenergic receptor
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL1916
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P18825
Alpha-2C adrenergic receptor
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Alpha-2C adrenergic receptor is the right protein anchor across sources, using UniProt P18825 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why Alzheimer disease is currently framed as clinical signal support. It currently carries 1 linked drug in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelAlpha-2C adrenergic receptor
UniProt AccessionP18825
Component TypeProtein
Sequence Length462 aa

Alpha-2C adrenergic receptor

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as Alpha-2C adrenergic receptor, mapped to UniProt P18825. Sequence length is 462 aa.

Mapped IDP18825
Review nameAlpha-2C adrenergic receptor
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Clinical signal Open Targets-ready proxy

Alpha-2C adrenergic receptor shows clinical signal disease relevance led by Alzheimer disease.

Clinical signal Phase II
Alzheimer disease
1 linked drug · 1 direct · 1 efficacy
Linked drugORM-12741
Source · ChEMBL drug mechanism + indication proxy
Review Cue

How to read disease relevance

Start review with Alzheimer disease because it currently carries clinical signal support. Linked drugs include ORM-12741. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseaseAlzheimer disease
Strongest levelClinical signal
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

157
Approved
16
Phase III
31
Phase II
5
Phase I
Assay Mix

Activity Type Distribution

IC50916.0
KI1,802.0
EC50204.0
KD1.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL435352 10.52 Ki 0.03 Preclinical
CHEMBL4878875 10.07 IC50 0.085 Preclinical
CHEMBL2112985 10.0 Ki 0.1 Preclinical
CHEMBL176261 10.0 Ki 0.1 Preclinical
CHEMBL180470 10.0 Ki 0.1 Preclinical
CHEMBL91157 10.0 Ki 0.1 Preclinical
CHEMBL390718 10.0 Ki 0.1 Preclinical
CHEMBL1256414 9.89 Ki 0.1288 Preclinical
CHEMBL1255723 9.77 Ki 0.1698 Preclinical
CHEMBL419316 9.7 Ki 0.2 Preclinical
Distribution

pChEMBL Value Distribution

83
5.0
133
5.5
222
6.0
190
6.5
182
7.0
123
7.5
114
8.0
68
8.5
48
9.0
27
9.5
pChEMBL
Approved Drugs

Approved Drugs

LOFEXIDINE
CHEMBL17860
Approved 2018
BREXPIPRAZOLE
CHEMBL2105760
Approved 2015
CARIPRAZINE HYDROCHLORIDE
CHEMBL2024517
Approved 2015
SILODOSIN
CHEMBL24778
Approved 2008
PALIPERIDONE
CHEMBL1621
Approved 2006
ARIPIPRAZOLE
CHEMBL1112
Approved 2002
APOMORPHINE
CHEMBL53
Approved 2001
DEXMEDETOMIDINE
CHEMBL778
Approved 1999
DEXMEDETOMIDINE HYDROCHLORIDE
CHEMBL2106195
Approved 1999
MONTELUKAST
CHEMBL787
Approved 1998
QUETIAPINE
CHEMBL716
Approved 1997
PRAMIPEXOLE
CHEMBL301265
Approved 1997
RALOXIFENE
CHEMBL81
Approved 1997
TAMSULOSIN
CHEMBL836
Approved 1997
IRINOTECAN
CHEMBL481
Approved 1996
MIRTAZAPINE
CHEMBL654
Approved 1996
OLANZAPINE
CHEMBL715
Approved 1996
BRIMONIDINE
CHEMBL844
Approved 1996
CARVEDILOL
CHEMBL723
Approved 1995
NEFAZODONE HYDROCHLORIDE
CHEMBL1200492
Approved 1994
RISPERIDONE
CHEMBL85
Approved 1993
CISAPRIDE
CHEMBL1729
Approved 1993
AMLODIPINE
CHEMBL1491
Approved 1992
TICLOPIDINE
CHEMBL833
Approved 1991
SERTRALINE
CHEMBL809
Approved 1991
DOXAZOSIN
CHEMBL707
Approved 1990
EBASTINE
CHEMBL305660
Approved 1990
CLOMIPRAMINE
CHEMBL415
Approved 1989
CLOZAPINE
CHEMBL42
Approved 1989
PERGOLIDE
CHEMBL531
Approved 1988
ASTEMIZOLE
CHEMBL296419
Approved 1988
OXICONAZOLE
CHEMBL1262
Approved 1988
APRACLONIDINE
CHEMBL647
Approved 1987
RILMENIDINE
CHEMBL289480
Approved 1987
TERAZOSIN
CHEMBL611
Approved 1987
TERCONAZOLE
CHEMBL1714574
Approved 1987
OXYMETAZOLINE
CHEMBL762
Approved 1986
GUANFACINE
CHEMBL862
Approved 1986
TERFENADINE
CHEMBL17157
Approved 1985
SULCONAZOLE
CHEMBL1221
Approved 1985
HALOPROGIN
CHEMBL1289
Approved 1982
GENTIAN VIOLET
CHEMBL64894
Approved 1982
GUANABENZ
CHEMBL420
Approved 1982
TRAZODONE
CHEMBL621
Approved 1981
AMOXAPINE
CHEMBL1113
Approved 1980
MAPROTILINE
CHEMBL21731
Approved 1980
SULOCTIDIL
CHEMBL404849
Approved 1979
BROMOCRIPTINE
CHEMBL493
Approved 1978
CLEMASTINE
CHEMBL1626
Approved 1977
PRAZOSIN
CHEMBL2
Approved 1976
Assay Landscape

Assay Landscape

378
Total Assays
792
Tested Compounds
4
Assay Types
Binding — 300 assays, 792 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 219 374 6.8
cell-based format 77 320 7.2
cell membrane format 2 79 6.5
assay format 1 11 6.0
organism-based format 1 8 5.7
Functional — 69 assays, 182 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 49 127 7.0
assay format 19 54 8.3
cell membrane format 1 1 6.8
ADME — 7 assays, 5 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 6 5 6.2
single protein format 1 0
Unassigned — 2 assays, 1 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 2 1 5.2

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine